A retrospective study of VTE patients receiving outpatient pharmacotherapy with apixaban or warfarin in clinical practice showed that the risks of major bleeding and recurrent VTE were significantly lower among patients who received apixaban. These findings offer the first evidence on safety and effetiveness of apixaban in treating and preventing VTE in a real-world setting [1]. Results from the AMPLIFY trial show that the DOAC apixaban was non-inferior to low-molecular-weight heparin followed by warfarin in treatment of acute VTE. There was also significantly less major bleeding with apixaban [2]. According to clinical practice guidelines, DOACs are recommended over vitamin K antagonists (VKAs) for VTE without associated cancer diagnosis [3]. However, the safety and effectiveness of apixaban in the treatment of VTE in routine clinical practice had not been evaluated.
Thus, Weycker et al. compared the risk of major bleeding and recurrent VTE in an observational study among patients receiving apixaban vs warfarin for VTE in clinical practice in the USA. In this retrospective cohort, data was analysed from 4 private healthcare claims databases (between March 2014 and June 2017), including 19,676 patients on apixaban and 34,647 patients on warfarin. Patients were adults aged 18 years and over, who had initial VTE episodes and began outpatient treatment within 30 days with apixaban or warfarin plus parenteral anticoagulant bridge therapy. Major bleeding and recurrent VTE were ascertained during a 180-day follow-up period and were compared between apixaban and warfarin patients using Cox proportional hazards models. The crude incidence of major bleeding was 1.6% for apixaban (4.2 per 100 patient-years) vs 2.7% for warfarin (6.7 per 100 patient-years). The adjusted hazard ratio (HR) was 0.71 (95% CI, 0.63-0.82; P<0.001). The crude incidence of recurrent VTE was 2.4 for apixaban (6.4 per 100 patient-years) and 3.8% for warfarin (9.4 per 100 patient-years), with HR 0.77 (95% CI, 0.69-0.86; P<0.001). According to the researchers, this showed a clear difference between warfarin and apixaban regarding effectiveness and safety.
1. Weycker D, et al. Abstract 1298-373. ACC 2019, 16-18 March, New Orleans, USA.
2. Agnelli G, et al. N Eng J Med. 2013;369(9):799-809.
3. Kearon C, et al. Chest. 2016;149(2):315-52.
Posted on
Previous Article
« BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment Next Article
Ticagrelor monotherapy safe after dual antiplatelet therapy »
« BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment Next Article
Ticagrelor monotherapy safe after dual antiplatelet therapy »
Table of Contents: ACC 2019
Featured articles
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Substantial impact of temporary interruptions of warfarin versus DOAC
Smartwatch can detect atrial fibrillation with high degree of accuracy
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
High 5-year survival rates for older HF patients without initial severe comorbidity
Pulmonary Arterial Hypertension and Venous Thromboembolism
Interventional Cardiology
Vascular Medicine
Lower rates stroke/SE with DOACs in frail non-valvular AF patients
Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry
Convincing evidence of the role of icosapent in reducing subsequent CV events
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com